Results 231 to 240 of about 67,136 (328)

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet, Iain K. Robertson, Sharon P. Luccisano, Michelle L. Kilpatrick   +3 more
wiley   +1 more source

Barriers and Facilitators to Pharmacist-Led Deprescribing of Antihypertensives in Long-Term Care: A Survey-Based Study. [PDF]

Basic Clin Pharmacol Toxicol
Vucenovic A, Kraut RY, Manca DP, Sadowski CA.   +3 more
europepmc   +1 more source

The performance of pre-delivery serum concentrations of angiogenic factors in predicting postpartum antihypertensive drug therapy following abdominal delivery in severe preeclampsia and normotensive pregnancy

, 2019
Nnabuike Chibuoke Ngene, Jagidesa Moodley, Thajasvarie Naicker   +2 more
openalex   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Change in body mass index and disease burden among people with obesity and multiple long‐term conditions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a risk factor for multiple long‐term conditions (MLTCs/multimorbidity). However, the impact of weight loss in people with MLTCs is unclear. We investigated the association between body mass index (BMI) change and the development of obesity‐related complications (ORCs), as well as clinical and economic outcomes in individuals ...
Kamlesh Khunti, Alex Mourer, Silvia Capucci, Lua Wilkinson, Klaus K. Andersen, Abd A. Tahrani, Camilla S. Morgen   +6 more
wiley   +1 more source

Targeted Therapy for Hypertension in Pregnancy: Hemodynamics as a Therapeutic Compass. [PDF]

JACC Adv
Ceulemans M, Heremans R, Ghossein C, Gyselaers W.   +3 more
europepmc   +1 more source

Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer’s risk: a drug-target Mendelian randomization study [PDF]

Chunxiao Dang, Ruohan Wang, Yunzhen Shi, Pengfei Liu, Xiaofeng Wang, Jinxing Liu, Xiao Yu, Dongxu Jin, Qing Ma   +8 more
openalex   +1 more source

Association of metabolic obesity phenotypes with cognitive decline in the ELSA‐Brasil study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate the association between metabolic obesity phenotypes and cognitive decline and evaluate the potential mediating role of C‐reactive protein (CRP). Methods Longitudinal cohort study using three waves (2008–2019) of the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil).
Paulo Henrique Lazzaris Coelho, Natalia Gomes Gonçalves, Itamar S. Santos, Alessandra C. Goulart, Sandhi Maria Barreto, Luana Giatti, Paulo Caramelli, Paulo Andrade Lotufo, Isabela Martins Bensenor, Claudia Kimie Suemoto   +9 more
wiley   +1 more source

Blood Pressure Variability in Stroke: Building a Framework, Conceptualizing Intervention Opportunities, and Identifying Practical Research Objectives. [PDF]

Neurocrit Care
Rose DZ, Rabinstein AA, Kim-Tenser M, Bergese SD, Fontaine GV, Kircher C, Qureshi AI.   +6 more
europepmc   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source